Compare GMM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | IFRX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 86.0M |
| IPO Year | 2023 | 2017 |
| Metric | GMM | IFRX |
|---|---|---|
| Price | $1.28 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 17.4K | ★ 7.7M |
| Earning Date | 08-18-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | $0.72 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $0.71 |
| 52 Week High | $4.97 | $2.82 |
| Indicator | GMM | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 22.45 | 43.80 |
| Support Level | $1.23 | $0.92 |
| Resistance Level | $1.59 | $1.28 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 10.47 | 36.50 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.